Bailard, Inc. Novartis Ag Transaction History

Bailard, Inc.

$3.8 Billion
Q3 2024

A detailed history of Bailard, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Bailard, Inc. holds 5,680 shares of NVS stock, worth $586,573. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,680

Previous 4,087 38.98%

Holding current value

$586,573

Previous $435,000 50.11%

% of portfolio

0.02%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$106.13 - $120.89 $169,065 - $192,577	1,593 Added 38.98%	5,680 $653,000
Q2 2024 Jul 25, 2024	BUY	$92.57 - $107.37 $61,188 - $70,971	661 Added 19.29%	4,087 $435,000
Q1 2024 May 08, 2024	BUY	$95.27 - $108.47 $326,395 - $371,618	3,426 New	3,426 $331,000
Q1 2021 May 13, 2021	SELL	$83.5 - $98.47 $758,848 - $894,895	-9,088 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$78.07 - $94.43 $42,938 - $51,936	550 Added 6.44%	9,088 $858,000
Q3 2020 Nov 10, 2020	BUY	$82.14 - $91.0 $39,837 - $44,135	485 Added 6.02%	8,538 $742,000
Q2 2020 Aug 12, 2020	BUY	$80.93 - $91.1 $251,044 - $282,592	3,102 Added 62.65%	8,053 $703,000
Q1 2020 Apr 16, 2020	SELL	$70.67 - $99.01 $67,560 - $94,653	-956 Reduced 16.18%	4,951 $408,000
Q4 2019 Jan 31, 2020	SELL	$84.35 - $95.37 $2,783 - $3,147	-33 Reduced 0.56%	5,907 $559,000
Q3 2019 Oct 18, 2019	BUY	$85.54 - $94.26 $51,324 - $56,556	600 Added 11.24%	5,940 $516,000
Q2 2019 Jul 26, 2019	BUY	$75.4 - $92.8 $53,458 - $65,795	709 Added 15.31%	5,340 $487,000
Q1 2019 Apr 24, 2019	BUY	$75.32 - $86.15 $348,806 - $398,960	4,631 New	4,631 $446,000

Others Institutions Holding NVS

# of Institutions

1,433

Shares Held

133M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $222B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account